All News

Adults with relapsing multiple sclerosis (MS) who are treated with ozanimod have less gray matter volume loss than patients treated with interferon, according to a post hoc analysis from the phase 3 RADIANCE Part B trial. The research was presented at the 2019 American Academy of Neurology Annual Meeting.

This week, the top managed care news included HHS announcing a finalized rule requiring the disclosure of drug prices in television ads; a report finding high satisfaction with employer health coverage despite the cost; a study finding heart failure is surging among young adults.

During an oral presentation of abstracts at the American Academy of Neurology’s 2019 Annual Meeting in Philadelphia, Pennsylvania, held May 4-10, researchers presented findings that suggest that while pregnant women with multiple sclerosis (MS) are often viewed as high-risk by their physician, pregnancy did not seem to increase the risk of adverse obstetrical outcomes for patients nor their babies.

An analysis of adoption of and adherence to chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in the primary care setting unearthed disappointing results, finding suboptimal use of pulmonary function tests, no routine use of validated symptoms scales for diagnosis, and variation in pharmacotherapy.

Witnesses appearing before the Senate Judiciary Committee discussed the need to maintain innovation for new drug discoveries while ensuring patients have access to treatments for chronic diseases as well as potentially curative therapies. In addition, Senator John Cornyn, R-Texas, raised the idea of giving the Federal Trade Commission (FTC) more authority to cut through patent thickets; his office said later he will propose a bill doing just that.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo